top of page

Janssen acquired bermekimab, a drug indicated for multiple dermatological indications

Bermekimab is in development for atopic dermatitis and hidradenitis suppurativa


The Janssen Pharmaceutical Companies of Johnson & Johnson announced that it completed the acquisition of bermekimab along with certain employees from XBiotech Inc. for $750 million. The drug is in development for atopic dermatitis and hidradenitis suppurativa.





Bermekimab is an anti-IL-1 alpha monoclonal antibody (mAb) in Phase 2 development. The drug is in Phase 2 development for atopic dermatitis and hidradenitis suppurativa.


"Adding bermekimab to our pipeline and portfolio builds on our legacy in immuno-dermatology, while expanding our reach to two additional disease areas with immense unmet need: atopic dermatitis and hidradenitis suppurativa," said David M. Lee, Immunology Therapeutic Area Head, Janssen Research & Development.


XBiotech Inc. will also receive additional payments upon commercial authorizations. Janssen Biotech, Inc acquired the compound, Janssen Research & Development, LLC develop the product.


More on Johnson and Johnson

0 comments

Recent Posts

See All

GlaxoSmithKline (GSK) has presented positive results from the phase III trial of its MenABCWY vaccine candidate at the European Society for Paediatric Infectious Diseases. The vaccine combination was

bottom of page